Pharma industry veteran brings more than two decades of experience in sales, marketing, business development, and global market expansion to his new leadership role
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
Topiramate is the generic version of Supernus Pharmaceuticals’ Trokendi XR
The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
